Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Published in: Cancer Chemotherapy and Pharmacology 6/2017

01-06-2017 | Review Article

Neurotoxicity after high-dose methotrexate (MTX) is adequately explained by insufficient folinic acid rescue

Author: Ian Joseph Cohen

Published in: Cancer Chemotherapy and Pharmacology | Issue 6/2017

Login to get access

Abstract

Purpose

To challenge the view that the dose of folinic acid rescue after high-dose methotrexate (MTX) has no significance in the prevention of neurotoxicity and to present the minority view that neurotoxicity can be prevented by an adequate dose of folinic acid, without compromising treatment results. Several fallacies that led to the misunderstanding of post MTX neurotoxicity are presented.

Methods

Data mining using search engines was used to find relevant publications, and an e-mail survey of more than 60 authors of articles in this field was performed. All relevant articles identified were read in their entirety.

Results

Examples of clinical studies with neurotoxicity following inadequate rescue are given. Some studies demonstrated no neurotoxicity when adequate doses of folinic acid rescue were started 24–36 h after the start of HDMTX rescue even after mega doses of MTX. Rescue started after 42 h was associated with neurotoxicity except in patients with low serum MTX levels after 24 and 36 h. ALL protocols with neurotoxicity, especially BFM-like protocols, are presented. Protocol is reported in which single protocol changes prevented neurotoxicity.

Conclusions

From the published data, when folinic acid rescue is given in a sufficiently high enough dose and is started 24–36 h after the beginning of the methotrexate exposure, and virtually all forms of post MTX neurotoxicity can be prevented without compromising therapeutic results.
Literature
1.
Krull K, Cheung YT, Liu W, Fellah S, Reddick WE, Brinkman TM, Kimberg C, Ogg R, Srivastava D, Pui CH, Robison LL, Hudson MM (2016) Chemotherapy pharmacodynamics and neuroimaging and neurocognitive outcomes in long-term survivors of childhood acute lymphoblastic leukemia. J Clin Oncol 34:2644–2653CrossRefPubMedPubMedCentral
2.
Duffner PK, Armstrong FD, Chen L, Helton KJ, Brecher ML, Bell B, Chauvenet AR (2014) Neurocognitive and neuroradiologic central nervous system late effects in children treated on pediatric oncology group (POG) P9605 (standard risk) and P9201 (lesser risk) acute lymphoblastic leukemia protocols (ACCL0131): a methotrexate consequence? A report from the Children’s Oncology Group. J Pediatr Hematol Oncol 36:8–15CrossRefPubMedPubMedCentral
3.
Richards S, Pui CH, Gayon P, Childhood Acute Lymphoblastic Leukemia Collaborative Group (CALLCG) (2004) Systemic review and meta-analysis of randomized trials of central nervous system directed therapy for childhood acute lymphoblastic leukemia. Pediatr Blood Cancer 60:185–195CrossRef
4.
Larsen EC, Devidas M, Chen S et al (2016) Dexamethasone and high-dose methotrexate improve outcome for children and young adults with high-risk b-acute lymphoblastic leukemia: a report from Children’s Oncology Group Study AALL0232. J Clin Oncol 34:2380–2388CrossRefPubMed
5.
Cohen IJ (2004) Defining the appropriate dosage of folinic acid after high-dose methotrexate that will prevent neurotoxicity without rescuing malignant cells in the central nervous system. J Pediatr Hematol Oncol 26:156–163CrossRefPubMed
6.
Meadows AT, Evans AE (1976) Effects of chemotherapy on the central nervous system: a study of parental methotrexate in long term survivors of leukemia and lymphoma in childhood. Cancer 21:1079–1085CrossRef
7.
Cohen IJ, Vogel R, Matz S, Weitz R, Mor C, Stern S, Zaizov R (1986) Successful non - neurotoxic therapy (without radiation) of a multifocal primary brain lymphoma with a methotrexate, vincristine and BCNU protocol (DEMOB). Cancer 57:6–11CrossRefPubMed
8.
Allen JC, Rosen G, Mehta BM, Horten B (1980) Leukoencephalopathy following high-dose iv methotrexate chemotherapy with leucovorin rescue. Cancer Treat Rep 64:1261–1273PubMed
9.
Cohen IJ (2013) Challenging the clinical relevance of folinic acid over rescue after high dose methotrexate (HDMTX). Med Hypotheses 81:942–947CrossRefPubMed
10.
Winik NJ, Bowman WP, Kamen BA, Roach ES, Rollins N, Jacaruso D, Buchanan GR (1992) Unexpected acute neurotoxicity in the treatment of children with acute lymphatic leukemia. J Natl Cancer Inst 84:252–256CrossRef
11.
Makulu DR, Smith EF, Bertino JR (1973) Lack of dihydrofolate reductase activity in brain tissue of mammalian species: possible implications. J Neurochem 21:241–245CrossRefPubMed
12.
13.
Abelson HT, Fosburg M, Gorka C, Kornblith P (1978) Identification of dihydrofolate reductase in human central-nervous-system tumours. Lancet 1:184–185CrossRefPubMed
14.
Lampkin BC, Higgins GR, Hammond D (1967) Absence of neurotoxicity following massive intrathecal administration of methotrexate. Cancer 20:1780–1781CrossRefPubMed
15.
Spiegel RJ, Cooper PR, Blum RH, Speyer JL, McBride D, Mangiardi J (1984) Treatment of massive intrathecal methotrexate overdose by ventriculolumbar perfusion. N Eng J Med 311:386–388CrossRef
16.
Ettinger LJ (1982) Pharmacokinetics and biochemical effects of a fatal intrathecal methotrexate overdose. Cancer 50:444–450CrossRefPubMed
17.
Abelson HT (1978) Methotrexate and central nervous system toxicity. Cancer Treat Rep 62:1999–2001PubMed
18.
Shapiro WR, Allen JC, Horten B (1980) Chronic methotrexate toxicity to the central nervous system. Clin Bull 10:49–52PubMed
19.
Reddick WE, Glass JO, Helton KJ, Langston JW, Xiong X, Wu S, Pui CH (2005) Prevalence of leukoencephalopathy in children treated for acute lymphoblastic leukemia with high-dose methotrexate. AJNR Am J Neuroradiol 26:1263–1269PubMedPubMedCentral
20.
Waber DP, Tarbell NJ, Kahn CM, Gelber RD, Sallan SE (1992) The relationship of sex and treatment modality to neuropsychologic outcome in childhood acute lymphoblastic leukemia. J Clin Oncol 10:810–817CrossRefPubMed
21.
22.
Sirotnak FM, Moccio DM, Dorick DM (1978) Optimization of high-dose methotrexate and leucovorin rescue therapy in the L1210 leukemia and sarcoma 180 murine tumor models. Cancer Res 38:345–353PubMed
23.
Browman GP, Goodyear MDE, Levine MN, Russell R, Archibald SD, Young JEM (1990) Modulation of the antitumor effect of methotrexate by low-dose leucovorin in squamous cell head and neck cancer: a randomized placebo-controlled clinical trial. J Clin Oncol 8:203–208CrossRefPubMed
24.
Diddens H, Teufel T, Neithammer D (1978) High dose methotrexate therapy with leucovorin rescue. In vitro investigations on human osteosarcoma cell lines. Cancer Chemother Pharmacol 20:128–132
25.
Pinedo HM, Zaharko DS, Bull MB, Chabner BA (1976) The reversal of methotrexate cytotoxicity to mouse bone marrow cells by leucovorin and nucleosides. Cancer Res 36:4418–4424PubMed
26.
Svahn T, Mellgren K, Harila-Saari A, Åsberg A, Kanerva J, Jónsson Ó, Vaitkeviciene G, Stamm Mikkelssen T, Schmiegelow K, Heldrup J (2016) Delayed elimination of high dose methotrexate and use of carboxypeptidaseG2 in pediatric patients during treatment for acute lymphatic leukemia. Pediatr Blood Cancer. doi:10.​1002/​pbc.​26395 PubMed
27.
Allen CA, Walker R, Rosen G (1988) Preradiation high dose intravenous methotrexate with leucovorin rescue for untreated childhood brain tumors. J Clin Oncol 6:649–653CrossRefPubMed
28.
Cohen IJ (2007) Prevention of high-dose-methotrexate neurotoxicity by adequate folinic acid rescue is possible even after central nervous system irradiation. Med Hypotheses 68:1147–1153CrossRefPubMed
29.
Borsi JD, Wesenberg F, Stockland T, Moe PJ (1991) How much is too much? folinic acid rescue dose in children with acute lymphatic leukemia. Eur J Cancer 27:1006–1009CrossRefPubMed
30.
Seidel H, Moe PJ, Nygaard R, Nygaard K, Brede W, Borsi JD (1994) Evaluation of serious events in patients treated with protocols including methotrexate infusions. Pediatr Hematol Oncol 11:165–172CrossRefPubMed
31.
Skarby T, Anderson H, Heldrup J, Kanerva JA, Seidel H, Schmiegelow K, Nordic Society of Paediatric Haematology and Oncology (NOPHO) (2006) High leucovorin doses during high dose methotrexate treatment may reduce the cure rate in childhood acute lymphatic leukemia. Leukemia 20:1955–1962CrossRefPubMed
32.
Vezmar S, Schüsseler P, Becker A, Bode U, Jaehde U (2009) Methotrexate-associated alterations of the folate and methyltransfer pathway in the CSF of ALL patients with and without symptoms of neurotoxicity. Pediatr Blood Cancer 52:26–32CrossRefPubMed
33.
Lo Nogro L, Di Cataldo A, Schiliro G (2000) Acute neurotoxicity in children treated with B-lineage acute lymphatic leukemia (B ALL) treated with intermediate risk protocols. Med Pediatr Oncol 35:449–455CrossRef
34.
Rizzari C, Valsecchi MG, Aricò M, Conter V, Testi A, Barisone E, Casale F, Lo Nigro L, Rondelli R, Basso G, Santoro N, Masera G, Pediatrica Associazione Italiano Ematologia Oncologia (1993) Effect of protracted high dose l-Aspaginase given as a second exposure in the Berlin-Frankfort-Munster-based treatment: results of a randomized 9102 intermediate-risk childhood acute lymphatic leukemia study—a report from the Associazone Italiana Emetologia Oncologia. J Clin Oncol 19:1297–1303CrossRef
35.
Mennes M, Stiers P, Vandenbussche E, Vercruysse G, Uyttebroeck D, De Meyer G, Van Cool SW (2005) Attention and information processing in survivors of childhood acute lymphatic leukemia treated with chemotherapy alone. Pediatr Blood Cancer 44:479–486CrossRef
36.
Millot F, Suciu S, Philippe N, Children’s Leukemia Cooperative Group of the European Organization for Research and Treatment of Cancer et al (1993) Value of high dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster based protocol in increased-risk children with acute lymphatic leukemia and lymphoblastic leukemia: results of the European organization for research and treatment of cancer 58881 randomized phase 111 trial. J Clin Oncol 19:1935–1942CrossRef
37.
Camitta B, Mahoney D, Leventhal B et al (1994) Intensive intravenous methotrexate and mercaptopurine treatment of higher-risk non-T, non-B acute lymphocytic leukemia: a Pediatric Oncology Group study. J Clin Oncol 12:1383–1389CrossRefPubMed
38.
Mahoney DH Jr, Shuster JJ, Nitschke R, Lauer SJ, Steuber CP, Winick N, Camitta B (1998) Acute neurotoxicity in children with B-precursor acute lymphoid leukemia: an association with intermediate-dose methotrexate and intrathecal triple therapy—a pediatric oncology group study. J Clin Oncol 16:1712–1722CrossRefPubMed
39.
Bell B, Abish S, Shuster J, Camitta B (1997) Neurotoxicity (NT) in children with standard-risk acute lymphoblastic leukemia (ALL) on Pediatric Oncology Group (POG) 9405. Blood 90:559a
40.
Buizer AI, de Sonneville LM, van den Heuvel-Eibrink MM, Veerman AJ (2005) Chemotherapy and attention dysfunction in survivors of childhood acute lymphoblastic leukemia: effect of treatment intensity. Pediatr Blood Cancer 45:281–290CrossRefPubMed
41.
Cohen IJ (2007) Comparison of long-term neurocognitive outcomes in young children with acute lymphatic leukemia treated with cranial radiation or high-dose or very high-dose intravenous methotrexate. J Clin Oncol 25:734–735CrossRefPubMed
42.
Kamps WA, Bökkerink JP, Hakvoort-Cammel FG, Veerman AJ, Weening RS, van Wering ER, van Weerden JF, Hermans J, Slater R, van den Berg E, Kroes WG, van der Does-van den Berg A (2002) BFM-oriented treatment for children with acute lymphoblastic leukemia without cranial irradiation and treatment reduction for standard risk patients: result of DCLSG protocol ALL-8 (1991–1996). Leukemia 16:1099–1111CrossRefPubMed
43.
Veerman AJ, Kamps WA, van den Berg H, Dutch Childhood Oncology Group et al (2009) Dexamethasone-based therapy for childhood acute lymphoblastic leukemia: results of the prospective Dutch Childhood Oncology Group (DCOG) protocol ALL-9 (1997–2004). Lancet Oncol 10:957–966CrossRefPubMed
44.
Buendia MT, Lozano JM, Saurez GE, Saavendra C, Guevara G (2008) The impact of acute lymphatic leukemia on central nervous system results in Bogota Colombia. J Pedatr Hematol Oncol 30:643–650CrossRef
45.
Goren MP, Wright RK, Horowitz ME, Meyer WH (1986) Enhancement of methotrexate nephrotoxicity after cisplatin therapy. Cancer 58:2617–2621CrossRefPubMed
46.
Forster VJ, van Delft FW, Baird SF, Mair S, Skinner R, Halse C (2016) Drug interactions may be important risk factors for methotrexate neurotoxicity, particularly in pediatric leukemia patients. Cancer Chemother Pharmacol 78:1093–1096CrossRefPubMedPubMedCentral
47.
Keefe BA, Capizzi RK, Rudnick SA (1982) Methotrexate cytotoxicity for L5178/Asn –lymphoblasts: relationship of dose and duration of exposure to tumor cell viability. Cancer Res 42:1641–1645PubMed
48.
Shkalim-Zemer V, Ash S, Toledano H, Kollender Y, Issakov J, Yaniv I, Cohen IJ (2015) Highly effective reduced toxicity dose-intensive pilot protocol for non-metastatic limb osteogenic sarcoma (SCOS 89). Cancer Chemother Pharmacol 76:909–916CrossRefPubMed
49.
Shkalim Zemer V, Toladano H, Ash S, Cohen E, Yaniv I, Cohen IJ (2016) Factors affecting the upper limit of the methotrexate (MTX) levels achievable in children with brain tumors treated with high-dose intravenous methotrexate. J Pediatr Hematol Oncol 38:5544–5548CrossRef
50.
Mikkelsen TS, Sparreboom A, Cheng C, Zhou Y, Boyett JM, Raimondi SC, Panetta JC, Bowman WP, Sandlund JT, Pui CH, Relling MV, Evans WE (2011) Shortening infusion time for high-dose methotrexate alters antileukemic effects: a randomized prospective clinical trial. J Clin Oncol 29:1771–1778CrossRefPubMedPubMedCentral
51.
Cohen IJ, Wolff JE (2014) How long can folinic acid rescue be delayed after high-dose methotrexate without toxicity? Pediatr Blood Cancer 61:7–10CrossRefPubMed
52.
Mahoney DH Jr, Shuster J, Nitschke R et al (1998) Intermediate-dose intravenous methotrexate with intravenous mercaptopurine is superior to repetitive low-dose methotrexate with intravenous mercaptopurine for children with lower-risk B lineage acute lymphoblastic leukemia: a PediatricOncology Group phase III trial. J Clin Oncol 16:246–25412CrossRefPubMed
53.
Djerassi I, Kim JS (1976) Methotrexate and citrovorum factor rescue in the management of childhood lymphosarcoma and reticulum cell sarcoma (non-Hodgkin’s lymphomas): prolonged unmaintained remissions. Cancer 38:1043–1051CrossRefPubMed
54.
Camitta B, Holcenberg JS (1978) Safety of delayed leucovorin “rescue” following high-dose methotrexate in children. Med Pediatr Oncol 5:55–59CrossRefPubMed
55.
Spiegler BJ, Kennedy K, Maze R, Greenberg ML, Weitzman S, Hitzler JK, Nathan PC (2006) Comparison of long term neurocognitive outcomes in young children with acute lymphoblastic leukemia treated with cranial radiation or high-dose or very high-dose intravenous methotrexate. J Clin Oncol 24:3858–3864CrossRefPubMed
56.
Balis FM, Savitch JL, Bleyer WA, Reaman GH, Poplack DG (1985) Remission induction of meningeal leukemia with high-dose intravenous methotrexate. J Clin Oncol 3:485–489CrossRefPubMed
57.
Nathan PC, Whitcom T, Pl Wolters, Steinberg SM, Balis FM, Brouwers P, Hunsberger S, Feusner J, Sather H, Miser J, Odom LF, Poplack D, Reaman G, Bleyer WA et al (2006) Very high-dose methotrexate [33.6 g/m(2)] as central nervous system preventive therapy for childhood acute lymphoblastic leukemia: results of National Cancer Institute/Children’s Cancer Group trials CCG-191P, CCG134P and CCG144P. Leuk Lymphoma 47:2488–2504CrossRefPubMed
58.
Von Stackelberg A, Yamanak J, Escherich G et al (2011) Conventional Reinduction/consolidation type therapy versus short course high intensity combination chemotherapy as post induction treatment for childrenwith relapsed acute lymphoblastic leukemia. Early results of study BFM ALL-REZ 2002. Blood 118:397
59.
Joannon P, Oviedo I, Campell M, Tordecilla J (2004) High-dose methotrexate therapy of childhood acute lymphoblastic leukemia: lack of relation between serum methotrexate concentration and creatinine clearance. Pediatr Blood Cancer 43:17–22CrossRefPubMed
60.
Vermar S, Becker A, Bode U, Jaehde U (2003) Biochemical and clinical aspects of methotrexate neurotoxicity. Chemotherapy 49:92–104CrossRef
61.
Kingma A, Van Dommelen RI, Mooyaart EL, Wilmink JT, Deelman BG, Kamps WA (2002) No major cognitive impairment in young children with acute lymphatic leukemia using chemotherapy only: a prospective longitudinal study. J Pediatr Hematol Oncol 24:106–114CrossRefPubMed
62.
Rodgers J, Marckus R, Kearns P, Windebank K (2003) Attentional ability among survivors of leukemia treated without cranial irradiation. Arch Dis Child 88:147–150CrossRefPubMedPubMedCentral
63.
Hann I, Vora A, Harrison R et al (2001) UK medical research council’s working party on childhood leukaemia. Determinants of outcome after intensified therapy of childhood lymphoblastic leukaemia: results from medical research council United Kingdom acute lymphatic leukaemia XI protocol. Br J Haematol 113:103–114CrossRefPubMed
64.
Patte C, Auperin A, Michon J, Société Française d’Oncologie Pédiatrique et al (2001) The Société Française d’Oncologie Pédiatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia. Blood 97:3370–3379CrossRefPubMed
65.
Mcallister LD, Doolittle NC, Guastadisegni PE, Kraemer DF, Lacy CA, Crossen JR, Neuwelt EA (2000) Cognitive outcomes and long term follow up results after enhanced chemotherapy delivery for primary central nervous system lymphoma. Neurosurgery 46:51–61CrossRefPubMed
66.
Edelmann MN, Daryani VM, Bishop MW, Liu W, Brinkman TM, Stewart CF, Mulrooney DA, Kimberg C, Ness KK, Cheung YT, Srivastava DK, Robison LL, Hudson MM, Krull KR (2016) Neurocognitive and patient reported outcomes in adult survivors of childhood osteosarcoma. JAMA Oncol 2:201–208CrossRefPubMedPubMedCentral
67.
Bonda-Shkedi E, Weyl Ben Arush M, Kaplinsky C, Ash S, Goshen Y, Yaniv I, Cohen IJ (2013) The correlation between dose of folinic acid and neurotoxicity in children and adolescents treated for osteosarcoma with high-dose methotrexate (HDMTX): a neuropsychological and psychosocial study. J Pediatr Hematol Oncol 35:271–275CrossRefPubMed
68.
Sirotnak FM, Donsbach RC, Moccio DM, Dorick DM (1976) Biochemical and pharmacokinetic effects of leucovorin after high dose methotrexate in a murine leukemia model. Cancer Res 36:4679–4686PubMed
69.
Cohen IJ (2003) Progression of osteosarcoma after high dose methotrexate: over rescue by folinic acid. Pediatr Hematol Oncol 20:579–581CrossRefPubMed
70.
Cohen IJ (2009) High-dose methotrexate is effective in osteosarcoma so what is the problem? J Pediatr Hematol Oncol 31:892–894CrossRefPubMed
71.
Toft N, Birgens H, Abrahamsson J et al (2016) Toxicity profile and treatment delays in NOPHO ALL2008 comparing adults and children with Philadelphia chromosome-negative acute lymphoblastic leukemia. Eur J Haematol 96:160–169CrossRefPubMed
72.
Jacola LM, Krull KR, Pui CH, Pei D, Cheng C, Reddick WE, Conklin HM (2016) Longitudinal assessment of neurocognitive outcomes in survivors of childhood acute lymphoblastic leukemia treated on a contemporary chemotherapy protocol. J Clin Oncol 34:1239–1247CrossRefPubMedPubMedCentral
Metadata
Title
Neurotoxicity after high-dose methotrexate (MTX) is adequately explained by insufficient folinic acid rescue
Author
Ian Joseph Cohen
Publication date
01-06-2017
Publisher
Springer Berlin Heidelberg
Published in
Cancer Chemotherapy and Pharmacology / Issue 6/2017
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-017-3304-y

Other articles of this Issue 6/2017

Cancer Chemotherapy and Pharmacology 6/2017 Go to the issue

Original Article

Pharmacokinetics and safety of carfilzomib in patients with relapsed multiple myeloma and end-stage renal disease (ESRD): an open-label, single-arm, phase I study

Original Article

Assessment of drug–drug interaction potential between ceritinib and proton pump inhibitors in healthy subjects and in patients with ALK-positive non-small cell lung cancer

Original Article

Induction chemotherapy followed by concurrent chemoradiotherapy vs. concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: a retrospective cohort study

Original Article

Phase II study of S-1 plus bevacizumab combination therapy for patients previously treated for non-squamous non-small cell lung cancer

Original Article

MITF suppression by CH5552074 inhibits cell growth in melanoma cells

Original Article

Accelerating drug development by efficiently using emerging PK/PD data from an adaptable entry-into-human trial: example of lumretuzumab
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits